Nature
Options are emerging for the tens of millions of people who stop taking GLP-1 drugs because of side effects, cost or availability.
‘Directed’ evolution in the laboratory creates an editing tool that outperforms classic CRISPR systems.
With organoids, assembloids and a growing bioengineering toolkit, scientists are pushing the limits of human brain models.
Drug makers are scrambling to navigate an ‘existential threat’ to a once-celebrated technology.
3D structure of the tongue’s sweet-sensing protein could guide future food designs.
Next-generation obesity drugs will work differently from Ozempic and Wegovy — aiming to deliver greater weight loss with fewer side effects.
The FDA’s nod for suzetrigine bolsters confidence in the pharmaceutical industry’s strategy to target sodium channels.
How a tissue-swelling method brought super-resolution imaging to the masses.
Pulses of light and sound seem to have beneficial effects. But some argue it is too soon to market experimental devices.
The medication is the first in decades to have a different mode of action than do current drugs, achieving better symptom relief with fewer side effects.